BioNexus Gene Lab Corp Common stock (BGLC) — Cash Flow Quality Index
BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow Quality Index of -3.38x as of June 2024. Operating cash flow of $-672.27K is below net income of $199.10K, suggesting accrual-heavy earnings not yet converted to cash. Explore BGLC cash flow metrics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BioNexus Gene Lab Corp Common stock Cash Flow Quality Index (2018–2021)
Historical Cash Flow Quality Index for BioNexus Gene Lab Corp Common stock across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how aggressively does BioNexus Gene Lab Corp Common stock reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for BioNexus Gene Lab Corp Common stock (2018–2021)
Year-by-year earnings quality comparison for BioNexus Gene Lab Corp Common stock. For live market cap and the full company financial profile, see BGLC stock market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.01x | $9.16K | $751.57K | ▼ -97.6% |
| 2020 | 0.51x | $552.68K | $1.09 Million | ▲ +104.9% |
| 2018 | -10.36x | $-274.08K | $26.45K | — |